Adjuvant-driven antibody response to use cows as biofactories of anti-SARS-CoV-2 neutralizing antibodies in colostrum.

Cows produce a substantial amount of immunoglobulin in the colostrum, and nutraceutical products derived from these antibodies are gaining attention for their potential role in human viral disease prevention. The objective of our study was to develop an immunization schedule for pregnant cows to produce hyperimmune colostrum with antibodies presenting high avidity and neutralizing activity against SARS-CoV-2. The recombinant spike receptor-binding domain (RBD) from SARS-CoV-2, expressed using the Expi293F system and purified via Ni-affinity chromatography, was solubilized in (1) saponin (QuilA) or (2) a suspension of potassium and aluminum hydroxide (Alum).

Evaluation and characterization of lytic phages and their recombinant endolysins for control of Staphylococcus aureus aiming to mitigate bovine mastitis.

As a natural alternative to conventional antimicrobials, bacteriophages are emerging as highly effective biocontrol agents against Staphylococcus aureus and other pathogenic bacteria. Due to the wide diversity of S. aureus types and the emergence of antibiotic-resistant strains, the search for highly lytic and prevalent bacteriophages against S.

Evidence of the efficiency of reverse vaccinology against bovine parasites: A systematic review.

Reverse vaccinology is a novel vaccine development technology that uses genome and proteome analyses through bioinformatics to select antigenic epitopes capable of eliciting an immunological and protective response through a quick and cheap methodology. However, data on its use in animal health are scant and further research is advocated. Therefore, this systematic review aimed to evaluate the evidence of the efficiency of reverse vaccinology in the search for antigens against bovine parasites, as well as its perspectives and limitations.

Targeted therapeutic options in early and metastatic NSCLC-overview.

The complex therapeutic strategy of non-small cell lung cancer (NSCLC) has changed significantly in recent years. Disease-free survival increased significantly with immunotherapy and chemotherapy registered in perioperative treatments, as well as adjuvant registered immunotherapy and targeted therapy (osimertinib) in case of EGFR mutation. In oncogenic-addictive metastatic NSCLC, primarily in adenocarcinoma, the range of targeted therapies is expanding, with which the expected overall survival increases significantly, measured in years.